Atlantic Research Group Successfully Completes Work on Phase III Randomized, Multi-Center Clinical Trial Facilitating Lev Pharmaceuticals, Inc.'s BLA Submission

STAUNTON, Va.--(BUSINESS WIRE)--Atlantic Research Group (“ARG”) played a critical role in the BLA submission made to the U.S. Food and Drug Administration (FDA) by Lev Pharmaceuticals. Lev Pharmaceuticals submitted a BLA to the FDA on July 31, 2007, after the completion of the pivotal U.S. Phase III trial of C1 inhibitor for the treatment of hereditary angioedema (HAE), to be marketed as CinryzeTM. Lev relied on ARG’s experienced staff and TrialVistaTM, ARG’s recently launched Clinical Trial Management System (CTMS), to assist in the timely completion of the clinical trial.